The dynamics of selected local inflammatory markers to talc in the treatment of malignant pleural effusions

被引:5
|
作者
Habal, Petr [1 ,2 ]
Jankovicova, Karolina [2 ,3 ]
Omran, Nedal [1 ,2 ]
Kondelkova, Katerina [2 ,3 ]
Krejsek, Jan [2 ,3 ]
Mandak, Jiri [1 ,2 ]
机构
[1] Charles Univ Prague, Fac Med Hradec Kralove, Dept Cardiac Surg, Prague, Czech Republic
[2] Univ Hosp, Hradec Kralove, Czech Republic
[3] Charles Univ Prague, Fac Med Hradec Kralove, Dept Clin Immunol & Allergy, Prague, Czech Republic
来源
BIOMEDICAL PAPERS-OLOMOUC | 2013年 / 157卷 / 04期
关键词
malignant pleural effusion; thoracoscopy; talc; sCD-163; sTLR-2; TOLL-LIKE RECEPTORS; EXPRESSION; PLEURODESIS; SURVIVAL; PATHOPHYSIOLOGY; MECHANISMS; CYTOKINES; IMMUNITY; POUDRAGE; FLUID;
D O I
10.5507/bp.2012.095
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Background. Malignant pleural effusions accumulate in the space between the visceral (inner) layer covering the lungs and the parietal (outer) layer covering the chest wall. Larger effusions compress the pulmonary parenchyma resulting in increasing dyspnoea. Treatment is always local and palliative. Among others, chemical pleurodesis using talc can be performed in selected patients. Talc is hydrated magnesium silicate (chemically H2Mg3 (SiO3)(4)) and has been used for pleurodesis since 1935. Videothoracoscopic talc powder insufflation (talc poudrage) is the most effective. However, markers of inflammatory reactions to extraneous substances like talc are not fully understood. The aim of this study was to assess the course of local inflammatory changes in the pleural cavity after talc insufflation. Methods. The Department of Cardiac Surgery of the Faculty of Medicine and University Hospital in Hradec Kralove, treated 47 patients aged 65 on average; 29 males and 18 females with proven recurrent malignant pleural effusion of various aetiologies from January 2009 to December 2010. They were retrospectively divided into group A (40 patients) without recurring effusion, and group B (7 patients) with recurring effusion and the need for thoracentesis or chest drainage during the 9-month monitoring. Results. Major findings were made in soluble forms of cell receptors. Group B showed statistically higher levels of the anti-inflammatory form of sCD-163 receptor in pleural fluid before the talc poudrage. This showed limited ability to create an adequate inflammatory response to external stimuli. This group also showed lower levels of the inflammatory form of sTLR-2 receptor immediately after the talc insufflation. This revealed low local reactivity to external stimuli. The effect of the treatment was not influenced by morphologic tumour type. No statistically significant differences in postoperative complications were found. This confirmed the safety of both videothoracoscopy and treatment. Conclusions. There was no correlation between the type of malignant affection and the outcome of the chemical pleurodesis. Patients with relapsing effusion have higher values of concentration of anti-inflammatory sCD-163 in pleural fluid even before the application of talc, and lower levels of concentration of inflammatory sTLR-2 immediately after application of talc.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 50 条
  • [1] Thoracoscopic talc poudrage in malignant pleural effusions
    Aelony, Y
    King, RR
    Boutin, C
    CHEST, 1998, 113 (04) : 1007 - 1012
  • [2] Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis
    Zhang, Wen
    Zhao, Yun-long
    Li, Shao-jun
    Zhao, Ying-nan
    Guo, Nan-nan
    Liu, Bo
    JOURNAL OF CARDIOTHORACIC SURGERY, 2021, 16 (01)
  • [3] Talc Pleurodesis for the Management of Malignant Pleural Effusions in Japan
    Inoue, Takeo
    Ishida, Atsuko
    Nakamura, Miho
    Nishine, Hiroki
    Mineshita, Masamichi
    Miyazawa, Teruomi
    INTERNAL MEDICINE, 2013, 52 (11) : 1173 - 1176
  • [4] Talc mediates angiostasis in malignant pleural effusions via endostatin induction
    Najmunnisa, N.
    Mohammed, K. A.
    Brown, S.
    Su, Y.
    Sriram, P. S.
    Moudgil, B.
    Loddenkemper, R.
    Antony, V. B.
    EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (04) : 761 - 769
  • [5] Palliative Treatment of Malignant Pleural Effusions
    Horn, D.
    Dequanter, D.
    Lothaire, Ph
    ACTA CHIRURGICA BELGICA, 2010, 110 (01) : 32 - 34
  • [6] Management of malignant pleural effusions with indwelling pleural catheters or talc pleurodesis
    Srour, Nadim
    Amjadi, Kayvan
    Forster, Alan John
    Aaron, Shawn David
    CANADIAN RESPIRATORY JOURNAL, 2013, 20 (02) : 106 - 110
  • [7] Osteopontin is upregulated in malignant and inflammatory pleural effusions
    Moschos, Charalampos
    Porfiridis, Ilias
    Psallidas, Ioannis
    Kollintza, Androniki
    Stathopoulos, Georgios T.
    Papiris, Spyros A.
    Roussos, Charis
    Kalomenidis, Ioannis
    RESPIROLOGY, 2009, 14 (05) : 716 - 722
  • [8] PATHOPHYSIOLOGY AND TREATMENT OF MALIGNANT PLEURAL EFFUSIONS
    KREUSER, ED
    ZENTRALBLATT FUR CHIRURGIE, 1992, 117 (02): : 91 - 96
  • [9] Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study
    Korsic, Marta
    Badovinac, Sonja
    Cucevic, Branka
    Janevski, Zoran
    WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (23-24) : 963 - 969
  • [10] Malignant pleural effusions: Treatment with small-bore-catheter thoracostomy and talc pleurodesis
    Marom, EM
    Patz, EF
    Erasmus, JJ
    McAdams, HP
    Goodman, PC
    Herndon, JE
    RADIOLOGY, 1999, 210 (01) : 277 - 281